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Abstract
The role of an atherogenic diet in causing pulmonary fibrosis has received little attention and simvastatin has been shown to reduce
pulmonary fibrosis in animal models. To determine if an atherogenic diet can induce pulmonary fibrosis and whether simvastatin treatment
is beneficial by up-regulating heat shock protein 70 and 90. New Zealand white rabbits (n = 15) were divided: Group 1 (control); Group 2
(MC) received a normal rabbit diet with 1% methionine plus 0.5% cholesterol (atherogenic diet). Group 3 received the same diet as the MC
group plus 5 mg/kg/day simvastatin orally (MCS). After 4 weeks, the lungs were collected and analysed. Picrosirus red staining of lung
interstitial collagen content showed that the atherogenic diet increased fibrosis 2.9-fold (P < 0.05), bronchiole adventitial collagen was
increased 2.3-fold (P < 0.05) and bronchiole epithelium was increased 34-fold (P < 0.05), and simvastatin treatment severely reduced this
effect (P < 0.05). Western blot analysis showed that the atherogenic diet significantly reduced lung Hsp70 protein by 22% (P < 0.05) and
Hsp90 protein by 18% (P < 0.05) and simvastatin treatment did not affect this result. However, aortic hyper-responsiveness to vasocon-
strictors (angiotensin II and phenylephrine) were markedly reduced by simvastatin treatment. We report that an atherogenic diet stimulates
pulmonary fibrosis and reduces lung Hsp70/Hsp90 protein concentration. Simvastatin impairs this by mechanisms unrelated to Hsp70/
Hsp90, but possibly a reduction in angiotensin II receptor or alpha adrenergic receptor pathways. These results could have implications in
idiopathic pulmonary fibrosis.
Keywords: simvastatin fibrosis Hsp70 Hsp90 diet cholesterolmethionine
Introduction
Idiopathic pulmonary fibrosis (IPF) is a fibroproliferative disorder,
thought to be caused by and unregulated physiological response to
microinsults. It is characterized by interstitial alveolar fibrosis and cur-
rently, no therapy has proven to reduce this pathology [1]. Therefore,
the aetiology of the disease and novel therapies are being sought.
The role of a Western diet (high in fat, cholesterol and methionine)
in inducing pulmonary fibrosis has received little attention [2] but
recent evidence reveals a positive role for diet in the prevention of
lung disease. For example, homocysteine, which is formed by the
demethylation of the essential amino acid methionine, has a pro-
fibrotic role. Elevated plasma homocysteine (tHcy) is associated with
increased pulmonary fibrosis in a murine model [3]. In a rabbit
model, we have shown that a diet high in methionine leads to myocar-
dial fibrosis [4] and clinically, high plasma homocysteine is strongly
associated with myocardial fibrosis [5].
Heat shock proteins play a pivotal role in cellular protection.
The HSP family are powerful chaperones that help cells cope
with increased cellular misfolded and denatured proteins, thus
helping cells resist damage and apoptosis. Thus, a decrease in
HSPs impairs the ability of a cell to cope with stress, and thus
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become more prone to apoptosis and inflammation [6–8]. Hsp32
(haeme-oxygenase 1) induction has been previously reported to
provide protection against pulmonary hypertension in a non-diet
murine model [9], and induction of Hsp70 in the rat lung by
heat exposure can attenuate lung fibrosis [10], The role of
Hsp90 in the regulation of lung fibrosis is not clear, but a recent
review suggests that it could be a promoter of cystic fibrosis
[11].
It remains unclear if simvastatin treatment can improve pulmo-
nary disease in the clinical setting [12]. Cell culture studies on lung fi-
broblasts show that simvastatin can inhibit the induction of collagen
production by transforming growth factor b [13] and studies in mice
show that simvastatin can impair bleomycin-induced pulmonary
fibrosis [14]. In other cell culture studies, simvastatin has been
shown to not up-regulate Hsp70 or Hsp90 proteins in osteoblasts
[15], but whether or not this effect of statin therapy also extends into
dietary-induced pulmonary fibrosis is unclear. Moreover, it is
unknown if a protective effect of simvastatin could be because of a
reduction in Hsp90 protein.
Furthermore, over stimulation of the renin angiotensin system
[16] and alpha adrenergic system [17] also play a major role in pul-
monary fibrosis. Finally, we used an atherogenic rabbit model known
to induce myocardial fibrosis [4] to study pulmonary fibrosis, and
whether simvastatin treatment can ameliorate these alterations via
changes in lung Hsp70 and Hsp 90 proteins or reactivity to angioten-
sin II and an alpha adrenergic agonist.
Materials and methods
Animals
Male New Zealand White rabbits at 3 months of age (weight range
between 2.8 and 3.2 kg) were randomized into 3 groups and fed a
specified dietary regimen for 4 weeks, and housed in individual cages
and maintained at a constant temperature of approximately 21°C. Food
and water were supplied ad libidum. The experiments were carried out
according to the National Health and Medical Research Council ‘Austra-
lian Code of Practice for the Care and Use of Animals for Scientific Pur-
poses’ (6th Edition, 1997).
Diet
Group (1) control (n = 5, Con); Group (2) received a normal rabbit
chow diet supplemented 0.5% cholesterol + 1% methionine + 5% pea-
nut oil (n = 5, MC) and Group (3) received a normal rabbit chow diet
supplemented 0.5% cholesterol + 1% methionine + 5 mg/kg/day sim-
vastatin orally + 5% peanut oil (n = 5, MCS).
Methods
Blood was collected weekly from all animals from the main ear artery
and immediately spun at 2236g for 5 min. and the serum collected and
snap frozen in liquid nitrogen. The animals were then killed by an over-
dose intra venous injection of ketamine and xylazine via the main ear
vein as previously described in our laboratory [18, 19]. The lungs were
then excised and immediately frozen in liquid nitrogen.
Western blot analysis
Lung samples (15 mg) were collected from 15 rabbits and homoge-
nized in 1 ml lysis buffer (50 mM TrisHCl, pH 8.0, 150 mM NaCl, 1%
NP-40, 0.5% Sodium Deoxycholate, 0.1% SDS, 2 mM ethylenediamine-
tetraacetic acid, 1 mM phenylmethanesulfonyl fluoride, 1/100 Sigma II
cocktail, 1 mM NaF and 1 tablet of protease inhibitor cocktail that has
been diluted to 1 ml with water). Homogenized tissue was then con-
stantly agitated for 2 hrs at 4°C and centrifuged at 12879g for 5 min.
The supernatant was collected, aliquoted and stored at 40°C until
used for gel electrophoresis. Acrylamide gels were composed of 8%
separating gel overlaid with 5% stacking gel. 30 lg of protein were
loaded into each well and electrophoresis was carried out at 100 V for
1 hr and then 180 V for 45 min. Following the electrophoretic separa-
tion, the proteins were transferred onto an immune-blot Polyvinylidene
Fluoride membrane (15 min. at 15 V). After transfer, the immune-blot
PVDF membranes were washed 5 times for 3 min. each in Tris Buf-
fered Saline-Tween and blocked with a blocking solution containing 5%
non-fat milk powder in TBS for 45 min. The membranes were then
incubated on a rocking platform at slow speed, overnight, at room
temperature with Hsp70 (1:1000, cat. no. MAB3516; Millipore, Bays-
water, Victoria, Australia), Hsp90 (1:2000, cat. no. 1429-50; Abcam) or
a tubulin antibody (1:20,000, cat. no. T6074; Sigma-Aldrich). Then,
membranes were washed 5 times for 3 min. each in TBS-Tween and
then placed in a blocking solution containing a specific antimouse anti-
body conjugated to peroxidise (1:7500, cat. no. P0447; Dako).
Enhanced chemiluminescence solution was incubated for 1 min. at
room temperature on a very slow rocking platform. The bands on the
membrane were visualized using the Fuji Film LAS3000, and bands
were analysed using FujiFilm MultiGauge Software, Brookvale, NSW,
Australia.
Isometric tension
Thoracic aortae from each rabbit were dissected into 4 9 3 mm rings.
The four rings were sequentially mounted between two metal hooks in
organ baths attached to force displacement transducers (OB8; Zultek
Engineering, Melbourne, Australia).
The baths were filled with Krebs solution and kept at a constant
temperature of 37°C and continuously bubbled with 95% O2/5% CO2.
After 1 hr, vessels were gently stretched to a resting tension of 2.5 g.
After 15 min., the vessels were gently re-stretched to a resting tension
of 2.5 g. After the vessels reached plateau tension, maximum constric-
tion was determined by a high potassium Krebs solution (KPSS,
124 mM K+). After plateau (6 min.), vessels were repeatedly rinsed
with Krebs solution. After 45 min., the vessel rings were subjected to
a phenylephrine concentration curve (108–105 M, half log units).
After the final concentration of phenylephrine was added and the con-
striction reached plateau, the vessels were repeatedly washed with
Krebs solution and allowed to rest for 1 hr. Then, the vessel rings
were subjected to an angiotensin II concentration curve (109–106 M,
half-log units).
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Immunohistochemistry and collagen stain
Lung biopsies were randomly obtained (4 mm) form all animals and
mounted on a single chuck and sections were cut at 5 micron using a
cryostat at 20°C. Sections were allowed to dry and then immediately
fixed in 4% paraformaldehyde solution in 19 PBS, pH 7.3, for 10 min.
For immunohistochemistry, sections were dehydrated through graded
alcohols, delapidated through xylene, and antigenic sites exposed via
submersion of slides in molten paraffin at 61°C for 30 min. After this,
sections were processed through xylene, and rehydrated through alco-
hol and then water. Sections were placed in 19 PBS for 2 min. and
then incubated with 1% goat serum in 19 PBS for 20 min. Then sec-
tions were incubated with anti-Hsp70 antibody (1:50) or Hsp90 (1:100)
(diluted in 1% donkey serum in 10 mM Tris HCl, pH 7.4) overnight.
Immunohistochemistry was then performed as previously described
[20, 21].
For collagen, pilot experiments were carried out to determine the
appropriate concentration and time for staining. Duplicate sections
were placed in a 0.001%; 0.01%; 0.1%; 1% picrosirus red solution
(dissolved in picric acid) for 30, 45 and 60 min. The final duplicate
slides selected were at 0.1% picrosirus red at 45 min. incubation. This
allowed for the best contrast between red collagen and yellow back-
ground. Sections were washed, dehydrated and mounted with DPX
mounting media. Slides were placed under a 209 lens (Olympus
microscope, BX53; Macquarie Park, NSW, Australia) and images of in-
terstitium and bronchioles were randomly obtained (2 per biopsy)
using a digital camera (Leica DFC490; North Ryde, Australia). The hue,
intensity and saturation of the MCID analysis software (MCID Core;
A B
C D
Fig. 1 Interstitial fibrosis in the lung indicated by red (sirius red) staining, and background cells by yellow (picric acid). Collagen is observed in the
control lung (A) and excess collagen deposition in observed in the MC group (B), which is restored to control by simvastatin treatment (C). Quantifi-
cation of collagen showed an approximate threefold increase in collagen in MC (D, *P < 0.05 versus all groups). PA: proportional area.
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InterFocus Imaging, Linton, UK) were adjusted to obtain the red
stained collagen, but not the faintly stained red or yellow background.
The intensity and proportional area were recorded for collagen, and an
average was calculated from all images per animal as published by
our laboratory [4]. This was then repeated and both results were aver-
aged and the data tabulated.
Data analysis
All data points were analysed by ANOVA followed by a Dunnets post hoc
test. A P < 0.05 was accepted in all cases as significant. Vasoconstric-
tive responses were normalized to KPSS values. All data are expressed
as mean  SEM and normalized to control.
Results
At the end of the treatment, blood total cholesterol was raised in
both MC and MCS groups (9.3  2.9 and 8.8  2.7 mM respec-
tively, P < 0.05) versus control (1.1  0.2 mM). Low density
lipoprotein was raised in MC and MCS (5.5  1.1 and
6.2  2.6 mM respectively, P < 0.05) versus control
(0.32  0.02 mM). Plasma triglycerides were not different
between MC, MCS and control (2.2  1.4 mM, 1.8  0.7 mM
and 0.6  0.02 mM respectively). Plasma homocysteine was
raised in weeks 1–3, but not at the end of the experiment
between MC, MCS and control (20  2.1 lM, 33  9.1 lM and
19  1.1 lM respectively).
A
B
C
D
Fig. 2 Bronchiole adventitial and epithelial
fibrosis in the lung indicated by red (sirius
red) staining, and background cells by yel-
low (picric acid). Collagen is observed in
the adventitia but not epithelia of the con-
trol lung (A) and excess collagen deposi-
tion in adventitia and epithelia is observed
in the MC group (B), which is not
observed by simvastatin treatment (C).
Quantification of collagen (D) showed an
increase in collagen in MC, and reversed
by simvastatin treatment (*P < 0.05).
2650 ª 2015 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
Analysis of picrosirus red staining of collagen in the pulmonary
interstitium (Fig. 1A–D) of animals fed the atherogenic diet (MC
group) showed a significant increase in pulmonary interstitial collagen
(B, D) compared to control (2.9  0.4-fold versus 1.00  0.3-fold,
P < 0.05). Simvastatin treatment inhibited this effect and restored
collagen to control levels (0.72  0.25-fold versus 1.00  0.3-fold).
Bronchiole adventitial collagen (Fig. 2A–D) increased 2.3  0.2-fold
(P < 0.05) and simvastatin reduced this to 1.3  0.32-fold
(P < 0.05 versus MC, P = ns versus control). Also, bronchiole epi-
thelial cell collagen increased 34  5.5-fold (P < 0.05) and simvasta-
tin reduced this to 9.0  2.7-fold (P < 0.05 versus MC and control).
Western blot analysis of both pulmonary Hsp70 and Hsp90 pro-
teins (Fig. 3A–D) revealed that the atherogenic diet significantly
reduced Hsp70 protein by 23% (A, P < 0.05) and Hsp90 protein by
18% (B, P < 0.05) compared to control diet. Simvastatin treatment
had no effect on pulmonary Hsp70 or Hsp90 (Fig. 3A and B).
Immunohistochemistry for both Hsp70 and Hsp90 revealed positive
co-immunostaining in the endothelium of arterioles and on the
surface of alveoli (MC group only shown, Fig. 3C and D).
Vascular reactivity
After 4 weeks of dietary manipulation (Fig. 4A and B), phenylephrine-
induced vasoconstriction was also increased in both MC
(87.0  3.3%, P < 0.001) and MCS groups (68.2  13.4%,
P < 0.05) versus control (54.9  3.0%). Interestingly, the MC group
showed increased vasoconstriction to angiotensin II compared to
control (49.5  9.9 versus 19.4  2.1, P < 0.001), which did not
occur in the MCS group (25.3  2.6 versus 49.5  9.9, P < 0.01),
A B
C D
Fig. 3Western blot analysis showed that
the atherogenic diet caused a decrease in
pulmonary Hsp70 (*P < 0.05 versus con-
trol, A) and Hsp 90 (*P < 0.05 versus
control, B) which was not affected by sim-
vastatin treatment. Immunohistochemistry
revealed co-localization (arrows) of Hsp70
(C) and Hsp90 (D) in the alveolae and
endothelial layer of arterioles (9400). Only
MC group is shown.
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the vasoconstriction being virtually normalized by simvastatin treat-
ment when compared to control group (25.3  2.6 versus
19.4  2.1, P = ns).
Discussion
The major findings in this study are that (i) an atherogenic diet for
4 weeks stimulates the development of pulmonary fibrosis; (ii) sim-
vastatin therapy can inhibit this effect regardless of the lipid profile
and tHcy; (iii) an atherogenic diet reduces the protein expression of
pulmonary Hsp70 and 90 and (iv) simvastatin does not restore Hsp70
or Hsp90 during an atherogenic diet.
Nutrition is implicated in diverse pathological conditions, namely
cardiovascular disease and obesity. The link between diet and pulmo-
nary disease has received little attention [22–24], as exposure to
allergens, genetic factors, cigarette smoking are established aeti-
ological factors. In our study, we clearly show for the first time that
an atherogenic diet designed to mimic excess animal product intake
raises plasma LDL and homocysteine which leads to pulmonary inter-
stitial fibrosis. These results have direct implications in the aetiology
of IPF.
Inhibition of HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-
CoA) by statins is an established treatment for the prevention of
cardiovascular disease, and has recently been found to improve exer-
cise capacity in chronic obstructive pulmonary disease patients with
pulmonary hypertension [25]. The mechanisms might include a benefi-
cial effect on nitric oxide [26, 27] and inhibition of endothelin [25].
Here, we show that simvastatin can impair the increase in dietary-
induced pulmonary fibrosis, an affect clearly not related to either a
decrease in plasma cholesterol or homocysteine, indicative of the
pleiotropic role of simvastatin therapy. Although statin therapy has
been shown to improve exercise capacity in humans, the mechanisms
remain elusive – whether simvastatin stimulates the remodelling of
pulmonary structure to resemble ‘normal’ collagen content remains to
be elucidated. Indeed, it is established that statin treatment can reduce
Akt signalling [28] and suppress inflammation [29], proposing that
suppression of inflammatory signalling could reduce collagen accumu-
lation. Furthermore, recent studies associate statin use with the induc-
tion of pulmonary fibrosis [30]. Here we show that simvastatin can
reduce the induction of pulmonary fibrosis caused by an atherogenic
diet, and these effects of statin therapy on pulmonary fibrosis are sup-
ported in other models [31–33]. Thus, further studies aimed at under-
standing the mechanisms involved with simvastatin use in pulmonary
fibrosis are warranted.
The atherogenic diet caused a significant reduction in Hsp70
and Hsp90, which was associated with the increase in pulmonary
collagen content. Whether a direct causal relationship exists
between a reduction in Hsp70/Hsp90 and pulmonary fibrosis is
unclear. Although an increase in Hsp70 has been shown to protect
rats from pulmonary fibrosis [10], the opposite might not hold
true. Indeed, simvastatin therapy inhibited dietary-induced pulmo-
nary fibrosis without affecting both Hsp70/Hsp90, clearly indicating
that the reduction in these two proteins might not be causing the
fibrosis observed. Moreover, Hsp70 has been suggested to be a
sensitive marker for oxidative stress in arteries [34] and we have
observed an increase in Hsp70 in the coronary artery of rabbits
fed a similar diet [20]. We propose that the atherogenic diet is
impeding the signalling pathways which stimulate the up-regulation
of Hsp70 in the lung. Further research understanding the signalling
pathways linked to Hsp70 up-regulation will shed light on this phe-
nomenon.
Hsp90 has been recently identified as a possible promoter of
collagen deposition [11], suggesting that a decrease in this protein
should prevent the accumulation of collagen. We show that the ath-
erogenic diet does reduce Hsp90, possibly in an attempt to reduce
collagen deposition even though excess collagen deposition occurred
in this model. Further studies aimed at reducing Hsp90 protein could
help elucidate the role of Hsp90 in dietary-induced pulmonary fibro-
sis. As collagen accumulation was impaired by simvastatin treatment
regardless of Hsp90 protein levels, studies aimed at determining
A
B
Fig. 4 A Simvastatin treatment significantly reduced phenylephrine-
induced vasoconstriction compared to MC (*P < 0.05), however, this
did not return to control (*P < 0.05). (B) Simvastatin treatment signifi-
cantly reduced angiotensin II-mediated vasoconstriction compared to
MC (**P < 0.01, †P < 0.001) and this was not significant to control.
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Hsp90 protein activity in this model could further aid in understanding
the role for Hsp90 in collagen deposition.
Simvastatin has pleiotropic effects on endothelial nitric oxide syn-
thase (eNOS). We have currently shown that in these same animals,
simvastatin impaired the ability of the atherogenic diet to cause endo-
thelial dysfunction in blood vessels, and this was not associated with
an increase in aortic endothelial eNOS, changes in the phosphorylation
of eNOS at the threonine 495 site or serine 1177, but simvastatin treat-
ment significantly reduced endothelial caveolin-1 by 35% [35]. Consid-
ering an increase in caveolin-1 has been linked to pulmonary fibrosis
[36], studies in this model addressing the role of caveolin-1 in the
cause and reduction of pulmonary fibrosis in this model is warranted.
Interestingly, we found a reduction in angiotensin II-mediated
vasoconstriction in the aorta of the animals fed the atherogenic diet
treated with simvastatin. The role of angiotensin II in mediating pulmo-
nary fibrosis is well-established [37, 38], and the effect of simvastatin
in reducing angiotensin II-mediated signalling is well reported [39–
41]. Also, we found a reduction in alpha adrenergic-mediated vasocon-
striction (using phenylpherine) in the aorta of the animals fed the ath-
erogenic diet treated with simvastatin, but this did not return to
normal. Also, the role of adrenergic mechanisms in the pathogenesis
of fibrosis is being recognized [17] and the effect of simvastatin on
reducing adrenergic mechanisms is reported [42]. Thus, in this model,
it is possible that simvastatin treatment is reducing both angiotensin II
and adrenergic mechanism-mediated fibrosis. Further studies aimed
at establishing this link in pulmonary fibrosis will help establish
whether or not angiotensin II receptor blockers, adrenergic blockers
and/or statin therapy can be used to treat this condition.
In conclusion, we report that an atherogenic diet for 4 weeks can
increase pulmonary fibrosis in the rabbit, which is associated with
reduction in Hsp70 and Hsp90. We also show that simvastatin
impairs pulmonary fibrosis without affecting plasma lipids, tHcy lev-
els, or Hsp70 and Hsp90, but reduces angiotensin II and phenyleph-
rine-mediated aortic vasoconstriction. These results have direct
implications in the aetiology and treatment of IPF.
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